Free Trial

Halozyme Therapeutics (HALO) Earnings Date, Estimates & Call Transcripts

Halozyme Therapeutics logo
$55.98 +1.25 (+2.28%)
Closing price 04:00 PM Eastern
Extended Trading
$55.12 -0.86 (-1.54%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Halozyme Therapeutics Earnings Summary

Halozyme Therapeutics announced Q1 2025 earnings on May 6, 2025, reporting an EPS of $1.11, which topped the consensus estimate of $0.98 by $0.13. Quarterly revenue rose 35.2% year-over-year to $264.86 million, above analysts' expectations of $231.21 million. With a trailing EPS of $3.76 and a P/E Ratio of 16.32, Halozyme Therapeutics' earnings are expected to grow 31.50% next year, from $4.73 to $6.22 per share.

Upcoming Q2
Earnings Date
Aug. 5After Market ClosesEstimated
Consensus EPS
(May. 6)
$0.98
Actual EPS
(May. 6)
$1.11 Beat By $0.13
Actual Revenue
(May. 6)
$264.86M

Q1 2025 Earnings Resources

HALO Upcoming Earnings

Halozyme Therapeutics' next earnings date is estimated for Tuesday, August 5, 2025, based on past reporting schedules.

Get Halozyme Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Halozyme Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

HALO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

HALO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Halozyme Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany EPS GuidanceCompany Revenue Guidance
Q1 20252$0.88$0.93$0.91
Q2 20252$1.04$1.09$1.07
Q3 20252$1.31$1.41$1.36
Q4 20252$1.58$1.66$1.62
FY 2025 8 $4.81 $5.09 $4.95
Q1 20261$1.30$1.30$1.30
Q2 20261$1.42$1.42$1.42
Q3 20261$1.56$1.56$1.56
Q4 20261$1.71$1.71$1.71
FY 2026 4 $5.99 $5.99 $5.99
Q1 20271$1.83$1.83$1.83

Halozyme Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/5/2025
(Estimated)
--------
5/6/2025Q1 2025$0.98$1.11+$0.13$0.93$231.21M$264.86M
2/18/2025Q4 2024$1.17$1.19+$0.02$1.06$285.74M$298.01M
8/6/2024Q2 2024$0.73$0.91+$0.18$0.98$204.94M$231.40M
5/7/2024Q1 2024$0.64$0.71+$0.07$0.82$201.72M$195.88M
2/20/2024Q4 2023$0.77$0.75 -$0.02$0.85$235.25M$230.04M
11/6/2023Q3 2023$0.67$0.69+$0.02$0.77$219.47M$216.03M
8/8/2023Q2 2023$0.59$0.68+$0.09$0.80$201.91M$221.04M

Halozyme Therapeutics Earnings - Frequently Asked Questions

Halozyme Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 5th, 2025 based off last year's report dates. Learn more on HALO's earnings history.

Halozyme Therapeutics updated its FY 2025 earnings guidance on Tuesday, May, 6th. The company provided earnings per share (EPS) guidance of 5.300-5.700 for the period, compared to the consensus EPS estimate of 5.000. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

In the previous quarter, Halozyme Therapeutics (NASDAQ:HALO) reported $1.11 earnings per share (EPS) to beat the analysts' consensus estimate of $0.98 by $0.13. Learn more on analysts' earnings estimate vs. HALO's actual earnings.

The conference call for Halozyme Therapeutics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Halozyme Therapeutics's latest earnings report can be read online.
Read Transcript

Halozyme Therapeutics (NASDAQ:HALO) has a recorded annual revenue of $1.08 billion.

Halozyme Therapeutics (NASDAQ:HALO) has a recorded net income of $281.59 million. HALO has generated $3.76 earnings per share over the last four quarters.

Halozyme Therapeutics (NASDAQ:HALO) has a trailing price-to-earnings ratio of 16.32 and a forward price-to-earnings ratio of 11.84. The price/earnings-to-growth ratio is 0.42.

Halozyme Therapeutics's earnings are expected to grow from $4.73 per share to $6.22 per share in the next year, which is a 31.50% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:HALO) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners